(NASDAQ: CHRS) Coherus Biosciences's forecast annual revenue growth rate of 28.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Coherus Biosciences's revenue in 2024 is $257,244,000.On average, 2 Wall Street analysts forecast CHRS's revenue for 2024 to be $32,349,058,056, with the lowest CHRS revenue forecast at $28,178,622,000, and the highest CHRS revenue forecast at $36,519,494,112. On average, 2 Wall Street analysts forecast CHRS's revenue for 2025 to be $40,126,357,728, with the lowest CHRS revenue forecast at $31,560,056,640, and the highest CHRS revenue forecast at $48,692,658,816.
In 2026, CHRS is forecast to generate $67,628,692,800 in revenue, with the lowest revenue forecast at $67,628,692,800 and the highest revenue forecast at $67,628,692,800.